

# SEQUENCE LISTING



<110> Goulmy, Els

<120> METHOD FOR TYPING OF MINOR HISTOCOMPATIBILITY ANTIGEN  
HA-1

<130> 58994

<140> 09/269,250

<141> 1999-05-21

<160> 38

<170> PatentIn Ver. 2.1

<210> 1

<211> 377

<212> DNA

<213> Human

<400> 1

gtgagagcca cggggacacc gaggcctggg tggaagacag agccagaccc aagggaggat 60  
ggagggaggg acttggggag gctcagaagg gagggaggct cagatggcag ggagggctgt 120  
gtggaagagg ccatgacagc taaggctctg agggatgtgt aggagtttgg tgggggagtc 180  
cctgagcgta cactgggtca agagggtgcc cactttattt tttttaaagg atctgatggc 240  
aattaggagg gaaaggcaga ggaaatgtcc catgcacagg ctcagaaaca cggaaacaga 300  
gaatgcattt gggggccaag gtgtgggggt cgcctggtgt aggatgaagg catgacaacg 360  
ccaggcagaa gggcaat 377

<210> 2

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PRIMER

<400> 2

gtgctgcctc ctggacactg

20

<210> 3

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PRIMER

<400> 3

tggctctcac cgtcatgcag

20

<210> 4

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PRIMER

<400> 4

tggtctcac cgtcacgcaa

20

<210> 5

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PRIMER

<400> 5

gcattctctg tttccgtgtt

20

<210> 6

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PRIMER

<400> 6

cttaaggagt gtgtgctgca

20

<210> 7

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PRIMER

<400> 7

cttaaggagt gtgtgttgcg

20

<210> 8

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PRIMER

<400> 8

gctgtcatgg cctcttccac

20

<210> 9

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PRIMER

<400> 9

gcattctctg tttccgtgtt

20

<210> 10

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PRIMER

<400> 10

ggcagagagc cctcgcagcc

20

<210> 11

<211> 18

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PRIMER

<400> 11

gtgtgttgcg tgacggtg

18

<210> 12

<211> 15

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PRIMER

<400> 12

gtgtgttgcg tgacg

15

<210> 13

<211> 16

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PRIMER

<400> 13

tgtgtgttgc gtgacg

16

<210> 14

<211> 19

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PRIMER

<400> 14

tgtgtgctgc atgacggtg

19

<210> 15

<211> 18

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PRIMER

<400> 15

tgtgtgctgc atgacggt

18

<210> 16

<211> 18

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PRIMER

<400> 16

gtgtgctgca tgacggtg

18

<210> 17

<211> 9

<212> PRT

<213> HUMAN

<220>

<223> Wherein Xaa at position 3 represents a histidine (H) or an arginine (R) residue.

<400> 17

Val Leu Xaa Asp Asp Leu Leu Glu Ala

1

5

<210> 18

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PRIMER

<400> 18

gctcctgcat gacgctctgt ctgca

25

<210> 19

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PRIMER

<400> 19

gacgtcgtcg aggacatctc ccat

24

<210> 20

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PRIMER

<400> 20

gaaggccaca gcaatcgtct ccagg

25

<210> 21

<211> 30

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PRIMER

<400> 21

ccttgagaaa cttaaggagt gtgtgctgca

30

<210> 22

<211> 30

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PRIMER

<400> 22

ccttgagaaa cttaaggagt gtgtgttgcg

30

<210> 23

<211> 33

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PRIMER

<400> 23

ccggcatgga cgtcgtcgag gacatctccc atc

33

<210> 24

<211> 30

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PRIMER

<400> 24

ctacttcagg ccacagcaat cgtctccagg

30

<210> 25

<211> 27

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Exon  
fragments

<220>

<221> CDS

<222> (1)..(27)

<400> 25

gtg ttg cgt gac gac ctc ctt gag gcc

27

Val Leu Arg Asp Asp Leu Leu Glu Ala

1

5

<210> 26

<211> 9

<212> PRT

<213> Artificial Sequence

<223> Description of Artificial Sequence: Exon  
fragments

<400> 26

Val Leu Arg Asp Asp Leu Leu Glu Ala  
1 5

<210> 27  
<211> 27  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Exon  
fragments

<220>  
<221> CDS  
<222> (1)..(27)

<400> 27  
gtg ctg cat gac gac ctc ctt gag gcc  
Val Leu His Asp Asp Leu Leu Glu Ala  
1 5

27

<210> 28  
<211> 9  
<212> PRT  
<213> Artificial Sequence  
<223> Description of Artificial Sequence: Exon  
fragments

<400> 28  
Val Leu His Asp Asp Leu Leu Glu Ala  
1 5

<210> 29  
<211> 23  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Exon  
fragments

<400> 29  
gtgttgcggtg acggtgagag cca

23



<210> 30  
<211> 37  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Exon  
fragments

<400> 30  
ctcactccga ctctccccag cagacctcct tgaggcc

37

C1  
cont  
<210> 31  
<211> 39  
<212> DNA  
<213> Human

<220>  
<221> CDS  
<222> (1)..(39)

<220>  
<223> PCR Product

<400> 31  
gag tgt gtg ttg cgt gac gac ctc ctt gag gcc cgc cgc  
Glu Cys Val Leu Arg Asp Asp Leu Leu Glu Ala Arg Arg  
1 5 10

39

<210> 32  
<211> 13  
<212> PRT  
<213> Human  
<223> PCR Product

<400> 32  
Glu Cys Val Leu Arg Asp Asp Leu Leu Glu Ala Arg Arg  
1 5 10

<210> 33  
<211> 39  
<212> DNA

<213> Human

<220>

<221> CDS

<222> (1)..(39)

<220>

<223> PCR Product

<400> 33

gag tgt gtg ctg cat gac gac ctc ctt gag gcc cgc cgc 39  
Glu Cys Val Leu His Asp Asp Leu Leu Glu Ala Arg Arg  
1 5 10

<210> 34

<211> 13

<212> PRT

<213> Human

<223> PCR Product

<400> 34

Glu Cys Val Leu His Asp Asp Leu Leu Glu Ala Arg Arg  
1 5 10

<210> 35

<211> 78

<212> DNA

<213> Human

<220>

<223> PCR Product

<220>

<221> CDS

<222> (1)..(78)

<400> 35

gag tgt gtg ttg cgt gac gac ctc ctt gag gcc cgc cgc gag tgt gtg 48  
Glu Cys Val Leu Arg Asp Asp Leu Leu Glu Ala Arg Arg Glu Cys Val  
1 5 10 15

ctg cat gac gac ctc ctt gag gcc cgc cgc 78  
Leu His Asp Asp Leu Leu Glu Ala Arg Arg  
20 25

<210> 36  
<211> 26  
<212> PRT  
<213> Human  
<223> PCR Product

<400> 36  
Glu Cys Val Leu Arg Asp Asp Leu Leu Glu Ala Arg Arg Glu Cys Val  
1 5 10 15

Leu His Asp Asp Leu Leu Glu Ala Arg Arg  
20 25

C1  
cont  
<210> 37  
<211> 9  
<212> PRT  
<213> Human

<220>  
<223> Wherein Xaa at position 2 represents Isoleucine or  
Leucine

<400> 37  
Tyr Xaa Thr Asp Arg Val Met Thr Val  
1 5

<210> 38  
<211> 9  
<212> PRT  
<213> Human

<220>  
<223> Isolated Lysis-inducing peptides

<400> 38  
Val Xaa His Asp Asp Xaa Xaa Glu Ala  
1 5